Also published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial demonstrated that tirzepatide at the 15 mg dose produced an average weight loss of 22.5% of body weight over 72 weeks approaching results typically seen with bariatric surgery (Jastreboff et al., 2022, PMID: 35658024)
Wear for at least 4 hours (longer wear optional)
Pregnant or breastfeeding women should avoid these treatments, and regular medical supervision is crucial to monitor side effects and ensure safe use
Diabetes and obesity are chronic (long-term) diseases and therefore GLP-1 receptor agonists are intended for long-term treatment
It improves insulin sensitivity, making it easier for cells to utilize glucose and contributing to better blood sugar control a critical factor for those with diabetes or insulin resistance
5-amino-1-methylquinolinium has been found to reduce adipocyte size and lower plasma total cholesterol levels in diet-induced obese mice and improve muscle strength in aged mice 204,205 (Fig